ArticleJournal of current glaucoma practice
Decoding Corneal Endothelial Loss from Glaucoma Treatment: A Case-Control Stratification Analysis.
Article in Journal of current glaucoma practice. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim and background: To characterize the effects of glaucoma treatment on the corneal endothelium by quantifying corneal endothelial morphology in eyes with and without glaucoma using in vivo specular microscopy. Materials and methods: This is a case-control study of 304 eyes conducted at an ambulatory glaucoma clinic at a tertiary academic institution from August 2021 through July 2023. Primary outcomes include endothelial cell density (ECD), coefficient of variation (CV), and hexagonality (Hex). Images of the central corneal endothelium were obtained using a non-contact Konan NSP-9000 specular microscope (Konan Medical, Irvine, CA, United States). The highest quality image of each cornea was selected for analysis. Each corneal endothelial image was manually graded using the Center Method and analyzed using CellChek (Konan Medical, Irvine, CA, United States) software. Results: Glaucomatous eyes demonstrate significantly lower corneal ECD compared to control eyes and glaucoma suspect eyes. Topical glaucoma drop use, trabeculectomy, and glaucoma tube shunt surgery independently predict a significant reduction in corneal ECD. Alpha agonist, carbonic anhydrase inhibitor (CAI), and Rho-associated protein kinase (ROCK) inhibitor drops independently predict a significant reduction in corneal ECD, with ROCK inhibitors predicting the greatest absolute decrease. Conclusion: Eyes treated with topical drops, trabeculectomy, or glaucoma tube shunt implantation demonstrate lower corneal ECD compared to control eyes. Use of topical drops from the alpha agonist, CAI, and ROCK inhibitor classes predicts significant corneal endothelial cell loss. Clinical significance: These findings provide valuable clinical context for the medical management of glaucoma that may reduce adverse outcomes and preserve corneal function in patients receiving ocular hypotensive therapy. How to cite this article: Yang CD, Carbonell BAC, Hussey V,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.